Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1617Carcinoma, Renal Cell 497Urinary Bladder Neoplasms 459Carcinoma, Transitional Cell 233Breast Neoplasms 225Kidney Neoplasms 214Neoplasms 190Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 168Ovarian Neoplasms 161Melanoma 161Neoplasm Metastasis 142Lung Neoplasms 127Non-Muscle Invasive Bladder Neoplasms 104Pancreatic Neoplasms 101Stomach Neoplasms 99Uterine Cervical Neoplasms 91Squamous Cell Carcinoma of Head and Neck 86Endometrial Neoplasms 82Carcinoma, Hepatocellular 76Sarcoma 75Esophageal Neoplasms 71Head and Neck Neoplasms 68Adenocarcinoma 67Triple Negative Breast Neoplasms 65Colonic Neoplasms 53Testicular Neoplasms 52Disease 47Wilms Tumor 46Urologic Neoplasms 45

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle-invasive Bladder Urothelial Carcinoma × Genitourinary × 1 year × Clear all
NCT07279597 2025-12-19

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

Tongji Hospital

Phase 2 Not yet recruiting
45 enrolled
Genitourinary

Muscle-invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡